Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Colorectal Biologic Trials

Orlando, Florida

Colorectal cancer biologic therapy trials in Orlando, FL

4 colorectal cancer biologic therapy studies are recruiting participants at sites in Orlando as of November 18, 2026, according to ClinicalTrials.gov. Colorectal Biologic Trials can help you understand your options and connect with a study team.

Call (888) 413-6546
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Orlando at a glance

  • 4 studies are recruiting at a site in Orlando.
  • By phase: Phase 3 (4).
  • By sponsor: industry (4).
  • Most recent update to one of these records: November 12, 2026.

Studies recruiting in Orlando

Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Orlando Health Cancer Institute ( Site 0065)
    Registry record
    NCT06997497 · updated
  2. Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Exelixis
    Study site
    Orlando Health Cancer Institute
    Registry record
    NCT07750158 · updated
  3. A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    AdventHealth Medical Group Oncology and Hematology at Orlando
    Registry record
    NCT06662786 · updated
  4. A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    AdventHealth Cancer Institute
    Registry record
    NCT06750094 · updated

Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Orlando, FL on ClinicalTrials.gov.

Ask about studies near Orlando

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Florida

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.

Colorectal Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 413-6546

or send a short form

How should we reach you?

Call